Nivolumab Plus Brentuximab Vedotin for R/R Primary Mediastinal Large B-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
Blood Adv 2023 Jun 23;[EPub Ahead of Print], PL Zinzani, A Santoro, G Gritti, P Brice, PM Barr, J Kuruvilla, D Cunningham, J Kline, NA Johnson, N Mehta-Shah, JM Lisano, R Wen, A Akyol, AJ MoskowitzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.